First Car-T for an Autoimmune Disease Enters Clinic

Published on :

First Car-T for an Autoimmune Disease Enters Clinic Maryland-Based Cartesian Therapeutics Initiates CAR-T Clinical Trial in Myasthenia Gravis Gaithersburg, MD, November 5, 2019 – see full press release Founded in 2016 by a pair of MD/PhD scientists and serial life sciences entrepreneurs, Cartesian Therapeutics is out to rapidly translate discoveries into clinical trials, and trials into [….]

Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome

Published on :

Emerging T Cell Therapy Company NexImmune Receives First IND Clearance for Phase 1/2 Trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome October 31, 2019 07:30 ET | Source: NexImmune, Inc. IND clearance enables commencement of clinical trial to evaluate NEXI-001 in AML/MDS patients with relapsed disease after allogeneic stem cell transplant IND clearance validates Company’s Artificial Immune Modulation [….]

Intralytix Opens New HQ in Columbia, Maryland for Phage Research and Manufacturing Facility

Published on :

From left to right:

– Per Falk, President & CSO, Ferring Pharmaceuticals
– John Woloszyn, Founder, President & CEO, Intralytix, Inc.
– Calvin Ball, County Executive, Howard County, Maryland
– Alexander Sulakvelidze, Founder, EVP & CSO, Intralytix, Inc.
– Antoine Baule, CEO, Lesaffre Compagnie

Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors

Published on :

Adaptive Phage Therapeutics Completes $7M Financing Round with Several Strategic Investors October 04, 2019Original Press Release GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company founded to provide an effective therapeutic response to the global rise of multi-drug resistant (MDR) pathogenic bacteria, today announced that it has closed an oversubscribed, non-brokered financing, raising approximately $7 [….]

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO

Published on :

Viela Bio Rings Nasdaq Opening Bell in Highly Anticipated Biotech IPO October 3, 2019 It has been just 20 months since Viela Bio was founded and today Viela Bio CEO Bing Yao, surrounded by colleagues and family, rang the opening Nasdaq bell to begin their first day of trading (NASDAQ: VIE). Their journey to IPO [….]

Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform

Published on :

Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform With new funding, Arcellx furthers its cell therapy platform intended to address new therapies in oncology and autoimmune disease October 3, 2019 Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B [….]

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic

Published on :

BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic Frederick, Maryland, September 26, 2019:  BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and Development Authority (BARDA) valued at up to $67.4 million for the advanced development of its Smallpox Biodefense Therapeutic as a potential medical countermeasure (MCM) for [….]